Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy

Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy

Dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin remains the standard of care for all patients undergoing percutaneous coronary intervention (PCI). It is well-established that patients carrying CYP2C19 no function alleles have impaired capacity to...

Full description

Bibliographic Details
Main Authors: Anh B. Nguyen, Larisa H. Cavallari, Joseph S. Rossi, George A. Stouffer, Craig R. Lee
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
cytochrome P450 (CYP)
precision medicine
clopidogrel
pharmacogenomics
race and ethnicity
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.991646/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.991646/full

Similar Items